中国肺癌杂志2024，Vol.27Issue(2)：81-87,7.DOI:10.3779/j.issn.1009-3419.2024.102.10
驱动基因阴性非小细胞肺癌二线治疗中国专家共识
Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations
中国临床肿瘤学会非小细胞肺癌专家委员会 1周彩存1
作者信息
摘要
Abstract
For advanced non-small cell lung cancer(NSCLC)patients with negative driver gene mutations,chemo-therapy has always been the standard treatment option,and immune checkpoint inhibitors(ICIs)provide other treatment op-tion for these patients.At present,the first-line treatment can choose chemotherapy,anti-angiogenic drugs or immunotherapy.Although the initial treatment can achieve a certain clinical curative effect,disease progression or treatment failure is eventually unavoidable.The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically.An expert panel of respiratory medicine,pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations,aiming to provide guidances for Chinese clini-cians in choosing second-line treatment for NSCLC patients with negative driver gene mutations.关键词
肺肿瘤/免疫治疗/抗血管生成药物/驱动基因阴性/专家共识Key words
Lung neoplasms/Immunotherapy/Anti-angiogenic drugs/Negative driver gene mutations/Expert consensus引用本文复制引用
中国临床肿瘤学会非小细胞肺癌专家委员会,周彩存..驱动基因阴性非小细胞肺癌二线治疗中国专家共识[J].中国肺癌杂志,2024,27(2):81-87,7.
